Brief: Imunon And Break Through Cancer Commence Enrollment In A Phase 1/2 Clinical Study Of Imnn-001 In Combination With Avastin In Advanced Ovarian Cancer

Imunon

27/02/2023 13:43

Feb 27 (Reuters) - Imunon Inc  IMNN.O :
    * IMUNON AND BREAK THROUGH CANCER COMMENCE ENROLLMENT IN A
PHASE
1/2 CLINICAL STUDY OF IMNN-001 IN COMBINATION WITH AVASTIN IN
ADVANCED OVARIAN CANCER
    * STUDY WILL BE PARTIALLY FUNDED BY BREAK THROUGH CANCER
THROUGH
OVARIAN MINIMAL RESIDUAL DISEASE TEAM LAB

Source text for Eikon:  ID:nGNXHjjD9 
Further company coverage:  IMNN.O 

 ((Reuters.Briefs@thomsonreuters.com))